Cure My Disease

Don't miss your cure!

 Log in / Sign up

A Two-Pronged attack on sedentary aging: less sitting, more Nrf2

NCT ID NCT07792967

Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether reducing sedentary time and taking a supplement called PB125 can improve how older veterans with multiple chronic conditions respond to exercise. Researchers will measure blood vessel function, muscle strength, daily steps, and sitting time. The goal is to see if these approaches can break a cycle of inactivity and poor health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A behavioral program to reduce sitting and increase walking, plus a supplement called PB125 that targets the Nrf2 pathway
What this could lead to
If it works, this could point toward a way to make exercise more effective for veterans with multiple chronic conditions, improving strength, blood vessel health, and daily activity.
What could go wrong
This is an early-stage trial with a modest number of participants, so results may not apply broadly. The supplement and behavioral program may not produce meaningful changes, and any supplement carries potential side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Physically inactive, ≤5,000 steps/day 2. Multimorbidity Weighted Index between 6 to 11 3. Ability to sign informed consent 4. Montreal cognitive assessment (MOCA) exam score ≥26 5. Free-living and ambulatory prior to admission Exclusion Criteria: 1. Multimorbidity Weighted Index \< 6 or \> 11 2. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma 3. Currently on a weight-loss diet or body mass index (BMI) \> 35 kilograms per square meter (kg/m2) (a BMI of 35 kg/m2, which includes individuals that fall into to the Class I obesity category, has been selected to improve inclusion and generalizability to a greater percentage of the general population) 4. Human immunodeficiency virus (HIV) or hepatitis B or C 5. Recent anabolic or corticosteroids use (within 3 months) 6. Subjects with hemoglobin or hematocrit lower than accepted lab values 7. Alcohol abuse (\> 2 drinks per day) or drug abuse (inappropriate use of prescription medications or use of any illicit/illegal drugs for recreational use) 8. Unwilling to cease dietary supplements 4 weeks prior to initiation intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multimorbidity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multimorbidity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah, 84148-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.